Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers August 18, 2017
Pharmacy Choice - News - Generic Drugs - August 18, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

8/11/17 - Accelerating generic drug approvals will save lives and dollars
Scott Gottlieb is a little different from some of his more bureaucratic predecessors: He's listening. Last month, the commissioner of the Food and Drug Administration hosted a public meeting to solicit input from patients, care providers, and drug makers on how to improve the FDA's drug approval process and, just as importantly, expedite the introd
8/11/17 - Animal Health Generics 2017: Intellectual Property and Patents, Regulation Issues, Strategies for R&D and Generics Companies, Company Profiles, Industry Associates
The "Animal Health Generics 2017: Intellectual Property and Patents, Regulation Issues, Strategies for R&D and Generics Companies, Company Profiles, Industry Associates" report has been added to Research and Markets' offering.. Intellectual Property 2.1 Summary 2.2 Introduction 2.3 WIPO 2.4 Patents 2.4. 1 Types of patent 2.4. 2 Company example 2.
8/11/17 - CURE Pharmaceutical Enters Partnership to Distribute New Erectile Dysfuntion Drug Using Companys Proprietary CureFilm Into Asian Market [Times of Oman]
-CURE Pharmaceutical,, a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company, today announced that it has partnered with a leading pharmaceutical distribution company to deliver a generic erectile dysfunction drug on its patented, multilayer oral thin film, CureFilm, into the Asian market.
8/11/17 - Elite Pharmaceuticals Inc. Reports Financial Results for the First Quarter of Fiscal Year 2018 Ended June 30, 2017 and Provides Conference Call Information
Release date- 10082017- NORTHVALE, N.J- Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, announced results for the first quarter of fiscal year 2018 ended June 30, 2017. 'We continue our strategy of developing a diverse product line of generics and abuse-deterrent opioids
8/11/17 - Findings from C. Remuzat and Co-Researchers Advance Knowledge in Science (Supply-side and demand-side policies for biosimilars: an overview in 10...
By a News Reporter-Staff News Editor at Science Letter Investigators publish new report on Science. According to news reporting originating from Paris, France, by NewsRx correspondents, research stated, "This study aimed to provide an overview of biosimilar? Financial support for this research came from Sandoz International GmbH.
8/11/17 - John Snow Focuses Practice on Hatch-Waxman Work
Polsinelli, an Am Law 100 firm, announced today that intellectual property litigator John Snow joined its Chicago office as a shareholder. He has served as trial counsel for various patent litigations in U.S. federal courts and has experience counseling biosimilar manufacturers and formulating strategies regarding the BPCIA. Snow prepares and prose
8/11/17 - Plans to Increase Access to Cost-Effective Biosimilar Medicines Move Forward With Opening of Public Consultation - Minister Harris
The Ireland Department of Health issued the following news release:. The consultation will inform the development of Ireland's first National Biosimilar Medicines Policy, with the aim of increasing the use of these more cost-effective medicines in Ireland. Ireland can capitalise on the new biosimilar medicines being brought to market and deliver mo
8/11/17 - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfizer Inc. - PFE
On August 10, 2017, post-market, Pfizer disclosed that the U.S. Justice Department is investigating the Company's Greenstone generics business, advising investors that "e believe this is related to an ongoing antitrust investigation of the generic pharmaceutical industry." The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Ange
8/11/17 - Studies from National Institute of Allergy and Infectious Diseases (NIAID) Update Current Data on Biopharmaceuticals (Biosimilars: Imitation Games)
According to news reporting originating from Gaithersburg, Maryland, by NewsRx correspondents, research stated, "Biopharmaceutical sales were at $160 billion in 2016. The news editors report that additional information may be obtained by contacting H. Dahodwala, Vaccine Production Program, VRC, NIAID, National Institutes of Health, 9 West Watkins M
8/10/17 - Another McCaskill Bill to Become Law: Plan With Collins to Tackle Cost of Rx Drugs Headed to President's Desk
Bipartisan legislation from U.S. Senator Claire McCaskill and Republican Senator Susan Collins of Maine to increase competition for generic drugs and help lower prescription costs now heads to the President's desk to be signed into law. "Drug companies should not be able to increase their prices dramatically by thousands of percent overnight witho
8/10/17 - Aurobindo Pharma to increase stakes in Tergene Biotech [India Infoline News Service]
Aurobindo Pharma plans to increase its stake in Tergene Biotech. Pharma sector player, Aurobindo Pharma plans to increase its stake in Tergene Biotech. Aurobindo Pharma Ltd is currently trading at Rs 714, up by Rs 29.85 or 4.36% from its previous closing of Rs 684.15 on the BSE.
8/10/17 - Branded Generics Market 2017 Global Trend, Segmentation and Opportunities Forecast To 2022
Branded Generics- Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2022. Wiseguyreports.Com Adds "Branded Generics- Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2022" To Its Research Database. This report studies the global Branded Generics market, analyzes and researches the Branded
8/10/17 - Cambrex Invests $24 Million in New Highly Potent API Manufacturing Capacity at its Charles City, Iowa Facility
Release date- 09082017- East Rutherford- Cambrex Corporation, the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients, today announced that it is to invest $24 million in a new facility to manufacture highly potent APIs at its Charles City, Iowa plant. 'This expansion is in line with Cambrex's commitment t
8/10/17 - CURE Pharmaceutical Enters Partnership to Distribute New Erectile Dysfuntion Drug Using Company's Proprietary CureFilm? Into Asian Market
CURE Pharmaceutical,, a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company, today announced that it has partnered with a leading pharmaceutical distribution company to deliver a generic erectile dysfunction drug on its patented, multilayer oral thin film, CureFilm?, into the Asian market..
8/10/17 - EpiPen maker cuts forecasts as generics suffer
The maker of the EpiPen allergy treatment revealed total revenues rose 16 per cent to $2.96 bn in the second quarter, but analysts were expecting sales to reach $3.03 bn according to Thomson Reuters. Mylan's net earnings rose 67 per cent to $297 m, or 55 cents per share. The erosion of generic prices and a delay in the timing of key new product lau
8/10/17 - Generic Drug Market Size & Share Will Reach USD 380.60 Billion by 2021: Zion Market Research
According to the report, the global generic drug market accounted for around USD 200.20 billion in 2015 and is expected to reach approximately USD 380.60 billion by 2021, growing at a CAGR of around 10.8% between 2016 and 2021.. Zion Market Research has published a new report titled "Generic Drug Market by Brand for Central Nervous System, Cardiova
8/10/17 - LUPIN EYES SPECIALITY BUSINESSES IN US
Lupin Limited, the pharmaceutical company of Mumbai, is planning to acquire speciality assets in women's health and neurology sectors in regulated markets like the USA. The strategy comes in the wake of pricing pressure in the generic drugs market in the USA. Lupin had acquired Gavis for $880 million in the USA in 2015, thus acquiring Methergine, a
8/10/17 - Mylan Advances Access in the Fight Against HIV with the Launch of Three Generic Antiretroviral Medicines in Canada
Mylan now offers generic alternatives to Truvada , Atripla and Viread to patients in Canada 1. HERTFORDSHIRE, England and PITTSBURGH and TORONTO, Aug. 10, 2017/ PRNewswire/ Mylan Pharmaceuticals ULC, a subsidiary of Mylan N.V., a leading global pharmaceutical company, today announced the launch in Canada of three generic products indicate
8/10/17 - Mylan Launches Three Generic HIV Drugs in Canada
Mylan Pharmaceuticals ULC, a subsidiary of Mylan N.V., announced the launch of three generic products in Canada for the treatment of HIV. Mylan received final approval from Health Canada for this product and for Mylan-Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate 600 mg, 200 mg, and 300 mg, a generic alternative to Atripla ; and Mylan-Ten
8/10/17 - Pharma Leader Series: Top Generic Drug Producers Market Forecast 2017-2027
North America, Europe, India, Japan, South Africa, MENA. The top 50 generic drug producers had combined revenues of $92 bn in 2016. The top 10 generic drug producers have 62% share of the total revenue made by these top 50 companies. 30% of the top 50 generic drug producers fall under the RoW region.
8/10/17 - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfizer Inc. - PFE
Pomerantz LLP is investigating claims on behalf of investors of Pfizer Inc.. On August 10, 2017, post-market, Pfizer disclosed that the U.S. Justice Department is investigating the Company's Greenstone generics business, advising investors that "e believe this is related to an ongoing antitrust investigation of the generic pharmaceutical industry
8/10/17 - Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) Targeting $500Million-$1 Billion On Medis Business Divestiture
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) plans to spin off its Medis Business, acquired with the purchase of Actavis last year. The divestiture is part of a cost saving strategy that the world's largest generic drug maker has embarked on after disappointing Q2 Earnings. Teva Divestitures The Israeli based drug maker values the Iceland
8/10/17 - US generics market slide reaches Taro [Globes, Tel Aviv, Israel]
Aug. 10 The fall of generic drug prices in the US is also affecting the results of Israeli company Taro Pharmaceutical Industries Ltd.. Taro is controlled by Indian company Sun Pharmaceutical Industries, whose chairman is Israel Makov. Over the past five years, however, Taro has given investors a return of over 150%, a result that other companies
8/9/17 - Another McCaskill Bill to Become Law: Plan with Collins to Tackle Cost of Rx Drugs Headed to President's Desk
WASHINGTON- Bipartisan legislation from U.S. Senator Claire McCaskill and Republican Senator Susan Collins of Maine to increase competition for generic drugs and help lower prescription costs now heads to the President's desk to be signed into law. "Drug companies should not be able to increase their prices dramatically by thousands of percent ove
8/9/17 - ARALEZ PHARMACEUTICALS INC. - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Forward-looking statements include, but are not limited to, statements about execution of our commercialization strategy with our expanded product portfolio, including Yosprala , Fibricor and its authorized generic, Toprol-XL and its currently marketed authorized generic and Zontivity , the benfits of the combination of POZEN Inc. and Tri
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415